Publication Name	World Journal of Clinical Cases
Manuscript ID	57136
Country	Italy

Received	2020-05-26 22:26
Peer-Review Started	2020-05-26 22:28
To Make the First Decision
Return for Revision	2020-06-15 17:40
Revised	2020-08-20 17:37
Second Decision	2020-09-07 10:15
Accepted by Journal Editor-in-Chief
Accepted by Company Editor-in-Chief	2020-09-08 00:50
Articles in Press	2020-09-08 00:50
Publication Fee Transferred
Edit the Manuscript by Language Editor
Typeset the Manuscript	2020-09-14 11:13
Publish the Manuscript Online	2020-09-28 01:45

ISSN	2307-8960 (online)
Open Access	This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Copyright	© The Author(s) 2020. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Infectious Diseases
Manuscript Type	Opinion Review
Article Title	Role of monoclonal antibody drugs in the treatment of COVID-19
Manuscript Source	Unsolicited Manuscript
All Author List	Claudio Ucciferri, Jacopo Vecchiet and Katia Falasca
Funding Agency and Grant Number
Corresponding Author	Katia Falasca, MD, PhD, Associate Professor, Clinic of Infectious Diseases, Department of Medicine and Science of Aging, University “G. d’Annunzio” Chieti-Pescara, Via dei Vestini, Chieti 66100, Italy. k.falasca@unich.it
Key Words	Tocilizumab; Anakinra; Canakinumab; Ruxolitinib; Clazakizumab; Siltuximab
Core Tip	Elevated inflammatory cytokines have been reported in patients with coronavirus disease 2019 (COVID-19). Evidence suggests that elevated cytokine levels and high levels in inflammatory markers are responsible for multi-organ damage in patients with COVID 19. Numerous randomized clinical trials are currently underway to explore the effectiveness of interleukin-1 blockers, interleukin-6 inhibitors. Or other strategies. For this reason it is necessary to make the point about using biopharmaceutical drugs in COVID 19.
Publish Date	2020-09-28 01:45
Citation	Ucciferri C, Vecchiet J, Falasca K. Role of monoclonal antibody drugs in the treatment of COVID-19. World J Clin Cases 2020; 8(19): 4280-4285
URL	https://www.wjgnet.com/2307-8960/full/v8/i19/4280.htm
DOI	https://dx.doi.org/10.12998/wjcc.v8.i19.4280

Full Article (PDF)	WJCC-8-4280.pdf
Full Article (Word)	WJCC-8-4280.docx
Manuscript File	57136-Review.docx
Answering Reviewers	57136-Answering reviewers.pdf
Audio Core Tip	57136-Audio core tip.opus
Conflict-of-Interest Disclosure Form	57136-Conflict-of-interest statement.pdf
Copyright License Agreement	57136-Copyright license agreement.pdf
Peer-review Report	57136-Peer-review(s).pdf
Scientific Misconduct Check	57136-Scientific misconduct check.pdf
Scientific Editor Work List	57136-Scientific editor work list.pdf